Vaginitis refers to the inflammation of vagina. It affects women of all ages but is most common during the reproductive years. Vaginitis occurs due to change in the balance of the yeast and bacteria that normally live in the vagina.


Download the sample report @ https://www.pharmaproff.com/request-sample/1151



















This causes the lining of the vagina to become inflamed. Use of antibiotics, changes in hormone levels due to pregnancy, breastfeeding, menopause, douching, spermicides, sexual intercourse and infection can change the normal balance of the vagina.

Get the detailed analysis @ https://www.pharmaproff.com/report/vaginitis-therapeutics-pipeline-analysis

The main symptom of vaginitis is increased discharge with a strong fishy odour. Itching is not common, but may be present if there is a lot of discharge. Vaginitis can be diagnosed by taking a sample of the discharge from vagina, which is then observed under a microscope. The treatment depends on the cause of the vaginitis. It may include a pill or a cream or gel that is applied to the vagina.

The drug candidates in vaginitis pipeline include, but are not limited to, Polygynax and Tamoxifen vaginal. Some of the companies in vaginitis therapeutics pipeline are Lumavita AG and Fulhold Pharma Limited.

Wnt signaling pathway plays an important role in embryonic development. The signaling pathway regulates cell-to-cell interaction, accelerates trophoblast development, activates blastocyst, accelerate chorion-allantois fusion and implantation. A wide range of diseases, such as different types of cancer and degenerative diseases can be treated by deregulation of components involved in Wnt/β-catenin signaling pathway. Also, researchers have demonstrated that moderate weakening of Wnt signaling can eliminate its carcinogenic potential. Based on the recent researches, Wnt Signaling Pathway inhibitors have also shown potential in cardiovascular disorders.

Get a sample report at: https://www.pharmaproff.com/request-sample/1210